High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infant
Ductus Arteriosus, Patent
About this trial
This is an interventional treatment trial for Ductus Arteriosus, Patent focused on measuring Patent ductus arteriosus, ibuprofen, preterm infants
Eligibility Criteria
Inclusion Criteria: Gestational age <29 weeks; an echocardiographic evidence of significant PDA; an age of 12 to 24 hours; and RDS necessitating respiratory support.
-
Exclusion Criteria: Major congenital anomalies; life-threatening infection or hydrops fetalis; pulmonary hypertension; death before the conclusion of the first course of ibuprofen; urine output below 1 ml per kilogram of body weight per hour during the preceding 12 hours (with the exception of the first dose); a serum creatinine concentration of >1.5 mg/dL (129 μmol per liter); a platelet count of <50,000/mm3; a tendency to bleed, as revealed by hematuria, blood in the endotracheal aspirate, gastric aspirate, or stools, and oozing from puncture sites.
-
Sites / Locations
- Careggi University Hospital, Division of Neonatology
Arms of the Study
Arm 1
Experimental
Infant treated with high dose ibuprofen